Home › Prostate Cancer › NCT06907446
Comparison of New SUREcore Biopsy of Needle to Standard of Care During Transperineal Prostate Biopsies
Comparison of BARD Max Core 18g Needle With Uro1 SUREcore 18g Needle in Targeted Prostate Biopsies
Who can join
Ages 18 and older · Men
Full eligibility criteria
Inclusion Criteria: * Patient older than age of 18 undergoing prostate biopsy Exclusion Criteria: * Unable to consent * Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives * Prisoners
About the study
To study a novel biopsy needle system for performing transperineal prostate biopsy. Prostate biopsy remains the standard approach for prostate cancer detection. While pre-biopsy MRI allows for targeting of visible lesions, systemic or 'off target' samples are recommended due to the well-recognized risk of undegrading and under sampling with current commercially available needles. The SureCore plus single-use biopsy needle produces a more intact tissue core with a same caliber 18g needle with \~21% more tissue per core in pre-clinical studies. This research study will determine if a new biopsy needle designed to produce more robust tissue cores per sample can improve detection and characterization of prostate cancer.
What is being tested
- Comparison of Biopsy Needle Types for Prostate Biopsy (diagnostic test)
Sponsor: University of California, Davis · Participants: 50 · Started: May 1, 2025
Contact the study team
- Marc Dall'Era, MD · Phone: 916-734-2893
- Elisa Lee · Phone: 916-734-5173
Official record on ClinicalTrials.gov — NCT06907446
Locations in the U.S.
| California | UC Davis Departments of Urologic Oncology, Sacramento |
Conditions
From ClinicalTrials.gov, data retrieved Oct 3, 2026. Each study sets its own eligibility; the study team decides who can join.